Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited

Country	Switzerland
Founded	2000
IPO Date	Oct 2, 2015
Industry	Medical Devices
Sector	Healthcare
Employees	1,605
CEO	Frank Leonard

Contact Details

Address: Neuhofstrasse 21 Baar, 6340 Switzerland
Website	novocure.com

Stock Details

Ticker Symbol	NVCR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001645113
CUSIP Number	G6674U108
ISIN Number	JE00BYSS4X48
SIC Code	3841

Key Executives

Name	Position
Frank Leonard	Chief Executive Officer
William F. Doyle	Executive Chairman
Christoph Brackmann	Chief Financial Officer
Michael Puri	Chief Human Resources Officer
Dr. Uri Weinberg M.D., Ph.D.	Chief Innovation Officer and Chief Medical Officer
Mukund Paravasthu	Chief Operating Officer
Adam Daney	Head of Investor Relations
Barak Ben-Arye	General Counsel

Latest SEC Filings

Date	Type	Title
May 8, 2026	SCHEDULE 13G/A	Filing
Apr 30, 2026	8-K	Current Report
Apr 30, 2026	10-Q	Quarterly Report
Apr 28, 2026	SCHEDULE 13G	Filing
Apr 24, 2026	8-K/A	[Amend] Current report
Apr 20, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 20, 2026	DEF 14A	Other definitive proxy statements
Apr 9, 2026	8-K	Current Report
Mar 26, 2026	SCHEDULE 13G/A	Filing
Mar 26, 2026	8-K	Current Report

View All SEC Filings